BoomRay Signs Exclusive $900 Million Radioligand Deal With Novartis
Chinese biotech BoomRay licenses a preclinical radioligand therapy to Novartis in a deal worth up to $900 million plus royalties.
/ 491 items
#XY Event-Driven Stocks↓
Amgen Drug Succeeds in Late-Stage Sjögren’s Disease Trial
Amgen’s dazodalibep met its Phase 3 goal in moderate-to-severe Sjögren’s disease, showing lasting improvement in systemic activity. A second trial is due later in 2026.
Vertex Inaxaplin Data Expands AMKD Market and Lifts Maze Outlook
Truist calls Vertex’s Phase 2b inaxaplin data a validation of APOL1 inhibition in AMKD and sees a 100,000+ extra patient opportunity, plus positive readthrough for Maze.
Lexeo Acquires Mantle for $8.3 Million to Expand Friedreich Ataxia Pipeline
Deal adds oral and brain-targeted FA treatments to Lexeo’s pipeline. LX2006 gene therapy stays top priority, with pivotal data due in late 2027.
Filana Gets FDA Green Light for Phase 2a Simufilam Study in TSC-Related Epilepsy
FDA lifted the clinical hold on Filana’s simufilam, clearing a Phase 2a study in TSC-related epilepsy. Lucid Capital keeps a Buy rating and $8 target.
Compass Therapeutics Slides After FDA Requests New Survival Trial for Tovecimig
Compass disagrees with the FDA, but markets sold off after the agency said existing ORR and PFS data are not enough for a tovecimig filing.